Table 4. The plasma hCAP-18 levels in patients with neutropenia secondary to an underlying condition or patients with acquired neutropenia, measured by immunoblot.
| Diagnosis (n) | hCAP-18 Immunoblot % |
|---|---|
| Congenital | |
| Shwachman-Diamond syndrome (1) | 0 |
| Barth syndrome (1) | 2 |
| Cohen syndrome (1) | 20 |
| Ataxia telangiectasia (1) | 90 |
| G6PD (1) | 42 |
| Graves’ disease (1) | 28 |
| Hyper IgE syndrome* (1) | 86 |
| Premature infant (2) | 23, 66 |
| STAT3, 5a, and 5b deletion (2) | 65, 100 |
| Developmental disorders (2) | 7, 37 |
| Unspecific immunodeficiency (1) | 27 |
| Acquired or therapy-induced | |
| Acute myeloid leukaemia (2) | 3, 23 |
| HHV6 infection (1) | 8 |
| Bacterial infection (1) | 108 |
| Drug (thiamazole) (2) | 9, 21 |
| Drug (low dose cytostatic) (3) | 36, 41, 134 |
| Others† | |
| SGD (2) | 1, 4 |
G6PD, glucose-6-phosphate dehydrogenase deficiency.
*The clinical characteristics of this patient has been described previously32.
†Patients without neutropenia but with neutrophil-specific granule deficiency (SGD).